TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02586779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whatsApp
Description: whatsApp application will be used for consultations.

Intervention type: OTHER
Group type: OTHER
Intervention: without whatsApp
Description: whatsApp application will be not used for consultations.
Study: NCT03485300

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver and kidney function tests for patients with chronic liver or kidney diseases
Description: Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected

Intervention type: BEHAVIORAL
Intervention: Non compliance of the patient
Description: I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up

Intervention type: DRUG
Intervention: Drug or food interactions
Description: The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
Study: NCT03419585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention systematic light exposure
Description: 30 minutes of intervention systematic light exposure daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison systematic light exposure
Description: 30 minutes of comparison systematic light exposure daily
Study: NCT04032509

Intervention type: OTHER
Intervention: 2 x 5 mL blood sample
Description: 2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
Study: NCT02547363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study: NCT00750152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT-500
Description: topical cream application up to 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo cream applied for up to 4 weeks
Study: NCT02125591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CN-NINM PoNS
Description: Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CN-NINM PoNS
Description: Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
Study: NCT00096356

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10 & Vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo & Vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Vitamin E
Study: NCT01008423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide will be administered as per the dose and schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
Study: NCT03762096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol
Description: 1 gram, twice a day by mouth Transmax (Biotivia)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00645450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly doses of placebo (inactive pill) following recollection of traumatic memory
Study: NCT02500940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Neoadjuvant chemotherapy regimen with cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Neoadjuvant chemotherapy regimen with cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Neoadjuvant chemotherapy regimen with Fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Neoadjuvant chemotherapy regimen with Fluorouracil

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Intensity-Modulated Radiation Therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Intensity-Modulated Radiation Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Neoadjuvant chemotherapy regimen with Leucovorin
Study: NCT02890641

Intervention type: GENETIC
Intervention: Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
Description: Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
Study: NCT00496938

Intervention type: DEVICE
Group type: OTHER
Intervention: XIENCE V®/ XIENCE PRIME™
Description: Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
Study: NCT02560025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Can be used in place of idarubicin
Study: NCT01094522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: 0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain.
Study: NCT00439816

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Visits
Study: NCT01687725

Intervention type: DEVICE
Intervention: Renal denervation using Symplicity Catheter system
Description: percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
Study: NCT04409860

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CCRT
Description: Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
Study: NCT01886989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols
Description: Cocoa polyphenols (960mg) reconstituted in water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa polyphenols
Description: Cocoa polyphenols (960mg) reconstituted in water
Study: NCT00852839

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match oromucosal formulation of 552-02

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 552-02
Description: The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
Study: NCT01106716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-1678
Description: KAI-1678 IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine
Study: NCT03854994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T Cells Injection
Description: Autologous genetically modified anti-CD19 CAR transduced T cells
Study: NCT04241900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shuttle run test
Description: At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
Study: NCT02034409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Low Intensity Ultrasound
Description: 20 minutes daily for 48 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: 20 minutes daily for 48 weeks
Study: NCT02047721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by \~2000 kcal/week.
Study: NCT03047824

Intervention type: DEVICE
Group type: OTHER
Intervention: Intravascular continuous monitoring
Description: Bedside usual insulin therapy guided by continuous glucose monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Bedside usual insulin therapy guided by intemittent glucose monitoring
Study: NCT02082756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium viable pharmaceutics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Hydrochloride
Study: NCT02894697

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI with BVS
Description: Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-guided PCI with BVS
Description: Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
Study: NCT01798160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DEB TACE
Description: DEB TACE every 6 weeks until either no viable tumor or endpoint reached.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIRT
Description: Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
Study: NCT03952949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Option While Online Grocery Shopping
Description: The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: The nutrition education materials were adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York).
Study: NCT00886847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Needle Tissue Collections
Description: Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
Study: NCT00638638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: * Abciximab: 0.25 mg/Kg bolus~* Abciximab placebo bolus~* Abciximab infusion 10 µg/Kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: * Abciximab: 0.25 mg/Kg bolus~* Abciximab placebo bolus~* Abciximab infusion 10 µg/Kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab placebo
Description: * Abciximab placebo Bolus~* Abciximab: 0.25 mg/Kg bolus~* Abciximab infusion 10 µg/Kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab placebo
Description: * Abciximab placebo Bolus~* Abciximab: 0.25 mg/Kg bolus~* Abciximab infusion 10 µg/Kg/min
Study: NCT01234935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT03675854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: 3 weeks
Study: NCT00160667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes.
Study: NCT00985777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E δ-Tocotrienol
Description: Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
Study: NCT01311167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Daily administration of 2 mg of dexamethasone for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of 2 mg of placebo for 4 days
Study: NCT02594020

Intervention type: PROCEDURE
Group type: OTHER
Intervention: air abrasion
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: air abrasion
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sono abrasion
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sono abrasion
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: dental bur
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: dental bur
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
Study: NCT04157673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 6-week, 8-week or 10-week baseline period.
Study: NCT00731926

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice a day for 1 month
Study: NCT01208363

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cowpea fortified with NaFeEDTA, in form of Toubani.
Description: 66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
Study: NCT02473146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Study: NCT00831493

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation (Radiation Therapy)
Description: Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
Study: NCT01420094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Description: Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter \[mL\]) between 1-4 hours post dental surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen (Tylenol extra strength)
Description: Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
Study: NCT02873949

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Crevicular samples (1-10µl)
Description: In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Crevicular samples (1-10µl)
Description: In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Saliva samples (1ml)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Saliva samples (1ml)

Intervention type: OTHER
Group type: OTHER
Intervention: Etiologic treatment
Description: education on oral hygiene, scaling and root planing

Intervention type: OTHER
Group type: OTHER
Intervention: Psychometric tests
Description: Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Psychometric tests
Description: Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
Study: NCT00022646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study: NCT02079272

Intervention type: OTHER
Group type: OTHER
Intervention: Helical tomotherapy for breast cancer
Description: 1. At baseline, before helical tomotherapy is performed, for each included woman will have:~   * measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, ..., microparticles and miRNA)~  * cardiologic examination including echocardiography for measurement of strain and strain rate~  * a CT coronary angiogram for measurement of coronary plaque indexes~2. Helical tomotherapy will be performed for all women included in the cohort.~3. At the end of tomotherapy, follow-up will include:~   * measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~  * cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~  * A CT coronary angiogram 24 months after radiotherapy
Study: NCT03013309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up 4 Health
Description: A parent-training intervention to improve child health and prevent/manage obesity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual